Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Recent & Breaking News (GREY:CLAZF)

Kalytera Reports Third Quarter 2018 Financial Results

GlobeNewswire November 30, 2018

The Future of CBD for Pain Treatment and Sports Medicine: Orion Nutraceuticals Inc. (CSE: ORI), Aurora Cannabis Inc., CannTrust Holdings Inc., Kalytera Therapeutics

GlobeNewswire November 20, 2018

Kalytera Announces Next Share Issuance for Services under Payments Agreement with Salzman Group

GlobeNewswire November 12, 2018

Advanced Cannabis Biopharma Company Announces ‘Pain’ Breakthrough

Jeff Nielson October 2, 2018

Kalytera Announces Next Share Issuance under Payments Agreements with Salzman Group

GlobeNewswire September 28, 2018

Kalytera Makes Progress with Acute and Chronic Pain Treatment

Stockhouse Editorial September 27, 2018

Kalytera Announces Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

GlobeNewswire September 27, 2018

Kalytera Announces Grant of Stock Options to Directors and Employees

GlobeNewswire September 24, 2018

Kalytera Therapeutics Provides Update for Lead Program in Prevention and Treatment of GVHD

GlobeNewswire September 20, 2018

IIROC Trading Resumption - KALY; KALY.WT

Canada NewsWire September 13, 2018

Kalytera Confirms No Material Change in Operations

GlobeNewswire September 13, 2018

IIROC Trading Halt - KALY; KALY.WT

Canada NewsWire September 13, 2018

Kalytera Announces Next Payment of Invoices in Shares under Payments Agreements with Salzman Group

GlobeNewswire September 7, 2018

Kalytera Reports Second Quarter 2018 Financial Results

GlobeNewswire August 30, 2018

Kalytera Provides Update on Arrangement with Former Shareholders of Talent Biotechs

GlobeNewswire August 24, 2018

Kalytera Announces Further Payments in Shares under Payments Agreements with Salzman Group

GlobeNewswire August 17, 2018

Kalytera Therapeutics, Inc. Announces Exercise of Over-Allotment Option

GlobeNewswire August 16, 2018

Kalytera Therapeutics, Inc. Announces Closing of Public Offering

GlobeNewswire August 8, 2018

Kalytera Completes Pre-IND Meeting with FDA

GlobeNewswire August 2, 2018

Kalytera Therapeutics Announces Adjournment of 2018 Annual and Special Meeting

GlobeNewswire July 27, 2018